Qianshan Pharmaceutical Machinery plans to acquire 754 million yuan for Lok Fu Land
On the evening of January 20, Qianshan Pharmaceutical Machinery announced that the company intends to purchase 100% equity of Hunan Lofudi Pharmaceutical Packaging Materials Technology Co., Ltd. by cash payment. According to the "Equity Transfer Agreement", the total consideration for the provisional transaction is 560.19 million yuan. Shenzhen Stock Exchange will conduct an after-the-fact review of the relevant documents of Qianshan Pharmaceutical Machinery's major asset restructuring. The company's stock will continue to be suspended from January 21, and will be notified of the resumption of trading after the audit results are obtained.
Based on downstream customer integration
The company's current research and development of polypropylene composite covers and interfaces for plastic container infusions has a good fit with the manufacturing operations of various injection production equipments of Qianshan Pharmaceutical Machinery, mainly reflected in the consistency of downstream customers. Business relevance.
Qianshan Pharmaceutical Machinery Co., Ltd. said that the existing businesses of listed companies and Loveland are mainly injecting injection enterprises with high consistency. The consistency of downstream customers is conducive to the integration after the completion of this transaction, to maximize the synergy of this acquisition.
In terms of future performance, all the counterparties of the transaction promised that the net profit attributable to the shareholders of the parent company after auditing and deducting non-recurring gains and losses will not be less than RMB 38 million in 2015 and not less than 5 in 2016. 10 million yuan, not less than 60 million yuan in 2017.
Market participants pointed out that the industrial upgrading of large infusion industry, soft plastic packaging infusion products (plastic bottles PP / PE and non-PVC soft bags) to replace glass bottles infusion has become a trend. In recent years, the proportion of glass infusions in China's large infusions has been declining year by year, and the infusion of plastic bottles and soft bags has increased rapidly. The sales volume of non-PVC soft bags has continued to grow steadily. The adjustment and upgrading of the product structure of the large infusion industry will drive the rapid development of the pharmaceutical packaging materials manufacturers, especially the new pharmaceutical packaging materials that are compatible with non-PVC soft bags and plastic bottles.
Fixed financing to prepare for M&A funds
Since 2014, as the enthusiasm for mergers and acquisitions has continued to heat up, the mode of financing and re-acquisition has continued to take place. The Qianshan Pharmaceutical Machinery has followed this path.
Qianshan Pharmaceuticals announced the issuance of a private placement plan at the end of August 2014. It plans to issue no more than 69 million shares to the major shareholders Liu Xianghua and Pi Xiaojun and Zheng Jun at a price of 19.26 yuan per share. The proposed fundraising will not exceed 1.258 billion yuan. . Among them, Liu Xianghua, chairman of Qianshan Pharmaceutical Machinery Co., Ltd. invested RMB 1.1 billion to subscribe for 58 million shares, and Pi Xiaojun and Zheng Jun subscribed for 6.23 million shares and 1.03 million shares respectively, and promised to lock the shares for three years.
At that time, Liu Xianghua, as the actual controller of Qianshan Pharmaceutical Machinery, had a lower shareholding ratio, accounting for only 13.72% of the company's share capital. By directional issuance, Liu Xianghua's shareholding ratio will increase to 33.66%. Liu Xianghua once said to the media, "The company is currently in a critical period of transformation. Business modules such as medical devices and gene sequencing are in urgent need of supporting funds for marketing. The increase in cash injection will accelerate the company's new profit growth. development of."
With the acquisition of Lok Fu Land's transaction surfaced, Qianshan Pharmaceutical Machinery has taken another step in expanding the industrial chain. Qianshan Pharmaceutical Machinery said that after the completion of the transaction, the total assets of the listed company, the shareholders' equity attributable to the parent company and the net profit attributable to the shareholders of the parent company will be improved, which will help further enhance the company's comprehensive competitiveness. Market expansion capability, resource control capability and follow-up development capability, enhance the company's profitability, enhance the listed company's ability to resist risks and sustainable development, in line with the interests of shareholders.
Protein Powder,Protein Collagen Powder,Hydrolysed Collagen Protein Peptide Powder,Hydrolyzed Collagen Powder Protein
Hebei Haodong Biological Technology Co.,Ltd. , https://www.hdgelatin.com